SMC1 promotes epithelial-mesenchymal transition in triple-negative breast cancer through upregulating Brachyury

Li,Kaichun; Ying,Mingzhen; Feng,Dan; Chen,Yan; Wang,Jingwen; Wang,Yajie

doi:10.3892/or.2016.4564

SMC1 promotes epithelial-mesenchymal transition in triple-negative breast cancer through upregulating Brachyury

Authors:
- Kaichun Li
- Mingzhen Ying
- Dan Feng
- Yan Chen
- Jingwen Wang
- Yajie Wang
View Affiliations

Affiliations: Department of Oncology, Changhai Hospital Affiliated to The Second Military Medical University, Shanghai 200433, P.R. China, Department of Pathology, Huadong Hospital Affiliated to Fudan University, Shanghai 200040, P.R. China, Department of Oncology, Huadong Hospital Affiliated to Fudan University, Shanghai 200040, P.R. China
Published online on: January 15, 2016 https://doi.org/10.3892/or.2016.4564
Pages: 2405-2412

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Triple-negative breast cancer (TNBC) is a special subtype of breast cancer, which is characterized by the negative form of estrogen receptor (ER), progesterone receptor (PR) and human epithelial growth factor receptor 2 (HER2). TNBC accounts for ~15% of all breast cancer forms, and often leads to high mortality and poor prognosis. Structural maintenance of chromosome 1 (SMC1) is a subunit of the cohesion protein complex. Brachyury is a protein that is encoded by the T gene in humans, which is a transcription factor within the T-box complex of genes. Epithelial-mesenchymal transition (EMT) is a ubiquitous process in the body, and in particular, induces metastasis and the proliferation of cancer cells. In the present study, we found that SMC1 expression in TNBC tissues exceeded its expression in adjacent non-tumor tissues. Similarly, the expression of SMC1 in TNBC cell lines (hs578T and HCC1937) was found to be higher than in MCF10a and MCF7 cells. Subsequently, SMC1 was overexpressed and silenced in hs578T and HCC1937 cells through plasmid and siRNA transfection, respectively. The results showed that the high expression of SMC1 often promoted EMT, accompanied by the enhanced expression of Brachyury. Besides, upregulated expression of Brachyury through plasmid transfection also significantly improved the level of EMT, which further indicated that SMC1 increased EMT in TNBC through the induction of Brachyury expression. Taken together, these results contributed to a better understanding of the pathogenesis of TNBC, which also provided an experimental basis for the prevention, diagnosis and treatment of TNBC.

View Figures

View References

1	Ossovskaya V, Wang Y, Budoff A, Xu Q, Lituev A, Potapova O, Vansant G, Monforte J and Daraselia N: Exploring molecular pathways of triple-negative breast cancer. Genes Cancer. 2:870–879. 2011. View Article : Google Scholar
2	Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA Jr, Ellis P, et al: Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol. 30:1879–1887. 2012. View Article : Google Scholar : PubMed/NCBI
3	Liu H, Scholz C, Zang C, Schefe JH, Habbel P, Regierer AC, Schulz CO, Possinger K and Eucker J: Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. Anticancer Res. 32:1627–1637. 2012.PubMed/NCBI
4	Stebbing J and Ellis P: An overview of drug development for metastatic breast cancer. Br J Nurs. 21:S18–S22. 2012. View Article : Google Scholar : PubMed/NCBI
5	Brouckaert O, Wildiers H, Floris G and Neven P: Update on triple-negative breast cancer: Prognosis and management strategies. Int J Womens Health. 4:511–520. 2012.PubMed/NCBI
6	Laugsch M, Seebach J, Schnittler H and Jessberger R: Imbalance of SMC1 and SMC3 cohesins causes specific and distinct effects. PLoS One. 8:e651492013. View Article : Google Scholar : PubMed/NCBI
7	Liu Z, Scannell DR, Eisen MB and Tjian R: Control of embryonic stem cell lineage commitment by core promoter factor, TAF3. Cell. 146:720–731. 2011. View Article : Google Scholar : PubMed/NCBI
8	Rhodes JM, McEwan M and Horsfield JA: Gene regulation by cohesin in cancer: Is the ring an unexpected party to proliferation? Mol Cancer Res. 9:1587–1607. 2011. View Article : Google Scholar : PubMed/NCBI
9	Nasmyth K and Haering CH: The structure and function of SMC and Kleisin complexes. Annu Rev Biochem. 74:595–648. 2005. View Article : Google Scholar : PubMed/NCBI
10	Yazdi PT, Wang Y, Zhao S, Patel N, Lee EY and Qin J: SMC1 is a downstream effector in the ATM/NBS1 branch of the human S-phase checkpoint. Genes Dev. 16:571–582. 2002. View Article : Google Scholar : PubMed/NCBI
11	Michaelis C, Ciosk R and Nasmyth K: Cohesins: Chromosomal proteins that prevent premature separation of sister chromatids. Cell. 91:35–45. 1997. View Article : Google Scholar : PubMed/NCBI
12	Hirano T: At the heart of the chromosome: SMC proteins in action. Nat Rev Mol Cell Biol. 7:311–322. 2006. View Article : Google Scholar : PubMed/NCBI
13	Rocquain J, Gelsi-Boyer V, Adélaïde J, Murati A, Carbuccia N, Vey N, Birnbaum D, Mozziconacci MJ and Chaffanet M: Alteration of cohesin genes in myeloid diseases. Am J Hematol. 85:717–719. 2010. View Article : Google Scholar : PubMed/NCBI
14	Yamamoto G, Irie T, Aida T, Nagoshi Y, Tsuchiya R and Tachikawa T: Correlation of invasion and metastasis of cancer cells, and expression of the RAD21 gene in oral squamous cell carcinoma. Virchows Arch. 448:435–441. 2006. View Article : Google Scholar : PubMed/NCBI
15	Yadav S, Sehrawat A, Eroglu Z, Somlo G, Hickey R, Yadav S, Liu X, Awasthi YC and Awasthi S: Role of SMC1 in overcoming drug resistance in triple negative breast cancer. PLoS One. 8:e643382013. View Article : Google Scholar : PubMed/NCBI
16	Naiche LA, Harrelson Z, Kelly RG and Papaioannou VE: T-box genes in vertebrate development. Annu Rev Genet. 39:219–239. 2005. View Article : Google Scholar : PubMed/NCBI
17	Showell C, Binder O and Conlon FL: T-box genes in early embryo genesis. Dev Dyn. 229:201–218. 2004. View Article : Google Scholar
18	Kilic N, Feldhaus S, Kilic E, Tennstedt P, Wicklein D, Wasielewski R, Viebahn C, Kreipe H and Schumacher U: Brachyury expression predicts poor prognosis at early stages of colorectal cancer. Eur J Cancer. 47:1080–1085. 2011. View Article : Google Scholar : PubMed/NCBI
19	Yang XR, Ng D, Alcorta DA, Liebsch NJ, Sheridan E, Li S, Goldstein AM, Parry DM and Kelley MJ: T (brachyury) gene duplication confers major susceptibility to familial chordoma. Nat Genet. 41:1176–1178. 2009. View Article : Google Scholar : PubMed/NCBI
20	Du R, Wu S, Lv X, Fang H, Wu S and Kang J: Overexpression of brachyury contributes to tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma. J Exp Clin Cancer Res. 33:1052014. View Article : Google Scholar : PubMed/NCBI
21	Huang B, Cohen JR, Fernando RI, Hamilton DH, Litzinger MT, Hodge JW and Palena C: The embryonic transcription factor Brachyury blocks cell cycle progression and mediates tumor resistance to conventional antitumor therapies. Cell Death Dis. 4:e6822013. View Article : Google Scholar : PubMed/NCBI
22	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mese nchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
23	Acloque H, Adams MS, Fishwick K, Bronner-Fraser M and Nieto MA: Epithelial-mesenchymal transitions: The importance of changing cell state in development and disease. J Clin Invest. 119:1438–1449. 2009. View Article : Google Scholar : PubMed/NCBI
24	Thiery JP and Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 7:131–142. 2006. View Article : Google Scholar : PubMed/NCBI
25	Savagner P: Leaving the neighborhood: Molecular mechanisms involved during epithelial-mesenchymal transition. BioEssays. 23:912–923. 2001. View Article : Google Scholar : PubMed/NCBI
26	Larue L and Bellacosa A: Epithelial-mesenchymal transition in development and cancer: Role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene. 24:7443–7454. 2005. View Article : Google Scholar : PubMed/NCBI
27	Christofori G: New signals from the invasive front. Nature. 441:444–450. 2006. View Article : Google Scholar : PubMed/NCBI
28	Kalluri R: EMT: When epithelial cells decide to become mesenchymal-like cells. J Clin Invest. 119:1417–1419. 2009. View Article : Google Scholar : PubMed/NCBI
29	Imajyo I, Sugiura T, Kobayashi Y, Shimoda M, Ishii K, Akimoto N, Yoshihama N, Kobayashi I and Mori Y: T-box transcription factor Brachyury expression is correlated with epithelial-mesenchymal transition and lymph node metastasis in oral squamous cell carcinoma. Int J Oncol. 41:1985–1995. 2012.PubMed/NCBI
30	Lim J and Thiery JP: Epithelial-mesenchymal transitions: Insights from development. Development. 139:3471–3486. 2012. View Article : Google Scholar : PubMed/NCBI
31	Fernando RI, Litzinger M, Trono P, Hamilton DH, Schlom J and Palena C: The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. J Clin Invest. 120:533–544. 2010. View Article : Google Scholar : PubMed/NCBI
32	Xu K, Liu B and Liu Y: Impact of Brachyury on epithelial-mesenchymal transitions and chemosensitivity in non-small cell lung cancer. Mol Med Rep. 12:995–1001. 2015.PubMed/NCBI